$ELAB
PMGC Holdings Inc. Stock $elab

$elab Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000121390024068592 Filed on August 14, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q2
Revenue	$527.5K	$605.5K	$320.0K
YoY Change	-99.9%	89.23%	88.24%
Cost Of Revenue	$133.6K	$166.3K	$110.0K
YoY Change	-99.93%	51.16%	83.33%
Gross Profit	$393.9K	$439.3K	$210.0K
YoY Change	-99.89%	109.17%	90.91%
Gross Profit Margin	74.68%	72.54%	65.63%
Selling, General & Admin	$1.215M	$1.385M	$1.120M
YoY Change	-99.84%	23.7%	220.0%
% of Gross Profit	308.43%	315.41%	533.33%
Research & Development	$95.26K	$52.39K	$130.0K
YoY Change	-99.89%	-59.7%	225.0%
% of Gross Profit	24.18%	11.93%	61.9%
Depreciation & Amortization	-$36.24K	$24.77K	$10.00K
YoY Change	2776.19%	147.7%
% of Gross Profit	-9.2%	5.64%	4.76%
Operating Expenses	$1.314M	$1.848M	$1.260M
YoY Change	-99.89%	46.66%	215.0%
Operating Profit	-$919.8K	-$1.409M	-$1.050M
YoY Change	-99.88%	34.15%	262.07%
Interest Expense	-$583.6K	-$4.120K	-$230.0K
YoY Change	-110.22%	-98.21%
% of Operating Profit
Other Income/Expense, Net	$1.340K	$0.00
YoY Change	-100.0%
Pretax Income	-$1.501M	-$1.412M	-$1.280M
YoY Change	91.72%	10.35%	341.38%
Income Tax
% Of Pretax Income
Net Earnings	-$1.501M	-$1.412M	-$1.280M
YoY Change	-99.81%	10.35%	341.38%
Net Earnings / Revenue	-284.61%	-233.27%	-400.0%
Basic Earnings Per Share	-$0.07	-$0.08	-$0.13
Diluted Earnings Per Share	-$0.07	-$0.08	-$0.07
COMMON SHARES
Basic Shares Outstanding	20.19M shares	18.89M shares	9.977M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.426M	$100.0K	$600.0K
YoY Change	1247.5%	-83.33%
Cash & Equivalents	$6.426M	$100.0K	$601.3K
Short-Term Investments
Other Short-Term Assets	$787.9K	$923.4K	$340.0K
YoY Change	169.76%	171.6%
Inventory	$986.4K	$978.5K	$480.0K
Prepaid Expenses
Receivables	$16.89K	$20.71K	$30.00K
Other Receivables	$11.00K	$8.360K	$0.00
Total Short-Term Assets	$8.228M	$2.031M	$1.450M
YoY Change	-99.36%	40.08%
LONG-TERM ASSETS
Property, Plant & Equipment	$52.53K	$55.75K	$280.0K
YoY Change	-99.91%	-80.09%
Goodwill
YoY Change
Intangibles	$2.824M	$2.845M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$10.77K	$10.00K
YoY Change	-100.0%	7.7%
Total Long-Term Assets	$2.978M	$3.049M	$290.0K
YoY Change	-99.03%	951.42%
TOTAL ASSETS
Total Short-Term Assets	$8.228M	$2.031M	$1.450M
Total Long-Term Assets	$2.978M	$3.049M	$290.0K
Total Assets	$11.21M	$5.080M	$1.740M
YoY Change	-99.29%	191.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.079M	$1.141M	$540.0K
YoY Change	88.23%	111.23%
Accrued Expenses	$137.6K	$40.81K	$210.0K
YoY Change	-49.7%	-80.57%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.130M	$1.935M	$1.560M
YoY Change	-99.87%	24.05%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$519.7K	$505.4K	$110.0K
YoY Change	403.06%	359.42%
Total Long-Term Liabilities	$519.7K	$505.4K	$110.0K
YoY Change	403.06%	359.42%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.130M	$1.935M	$1.560M
Total Long-Term Liabilities	$519.7K	$505.4K	$110.0K
Total Liabilities	$2.650M	$2.441M	$1.680M
YoY Change	-99.85%	45.27%
SHAREHOLDERS EQUITY
Retained Earnings	-$11.33M	-$9.834M
YoY Change	-99.81%
Common Stock	$19.89M	$12.47M
YoY Change	1865.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.555M	$2.640M	$67.29M
YoY Change
Total Liabilities & Shareholders Equity	$11.21M	$5.080M	$1.740M
YoY Change	-99.29%	191.97%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2023 Q2
OPERATING ACTIVITIES
Net Income	-$1.501M	-$1.412M	-$1.280M
YoY Change	-99.81%	10.35%	341.38%
Depreciation, Depletion And Amortization	-$36.24K	$24.77K	$10.00K
YoY Change	2776.19%	147.7%
Cash From Operating Activities	-$381.7K	-$780.7K	-$1.650M
YoY Change	-26.41%	-52.69%	236.73%
INVESTING ACTIVITIES
Capital Expenditures	$50.00K	$62.32K	$10.00K
YoY Change	4101.68%	523.2%	0.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$50.00K	-$62.32K	-$10.00K
YoY Change	4101.68%	523.2%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	6.758M	0.000	1.110M
YoY Change	1627.86%	-100.0%	136.17%
NET CHANGE
Cash From Operating Activities	-381.7K	-780.7K	-1.650M
Cash From Investing Activities	-50.00K	-62.32K	-10.00K
Cash From Financing Activities	6.758M	0.000	1.110M
Net Change In Cash	6.326M	-843.0K	-550.0K
YoY Change	-5012.88%	53.27%	2650.0%
FREE CASH FLOW
Cash From Operating Activities	-$381.7K	-$780.7K	-$1.650M
Capital Expenditures	$50.00K	$62.32K	$10.00K
Free Cash Flow	-$431.7K	-$843.0K	-$1.660M
YoY Change	-16.96%	-49.22%	232.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables		usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
	dei	Entity Shell Company EntityShellCompany	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41875
	dei	Entity Registrant Name EntityRegistrantName	ELEVAI LABS INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-1399981
	dei	Entity Address Address Line1 EntityAddressAddressLine1	Graydon Bensler
	dei	Entity Address Address Line2 EntityAddressAddressLine2	120 Newport Center Drive
	dei	Entity Address Address Line3 EntityAddressAddressLine3	Suite 250
	dei	Entity Address City Or Town EntityAddressCityOrTown	Newport Beach
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92660
	dei	City Area Code CityAreaCode	(866)
	dei	Local Phone Number LocalPhoneNumber	794-4940
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	ELAB
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	20192114	shares
	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	120000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	100034	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3326851	usd
CY2024Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	29070	usd
CY2023Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	36161	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	923444	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1060765	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	978548	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	495667	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	2031096	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	4919444	usd
CY2024Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	10773	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	10773	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	55751	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	53119	usd
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2845066	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	137535	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	206582	usd
CY2024Q2	us-gaap	Assets Assets	5080221	usd
CY2023Q4	us-gaap	Assets Assets	5189918	usd
CY2024Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1181441	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	669375	usd
CY2024Q2	us-gaap	Customer Deposits Current CustomerDepositsCurrent	24314	usd
CY2023Q4	us-gaap	Customer Deposits Current CustomerDepositsCurrent	36693	usd
CY2024Q2	us-gaap	Loans Payable Current LoansPayableCurrent	348403	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	140063	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	145000	usd
CY2024Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	67355	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	369158	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1935224	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1297353	usd
CY2024Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	505361	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	65489	usd
CY2024Q2	us-gaap	Liabilities Liabilities	2440585	usd
CY2023Q4	us-gaap	Liabilities Liabilities	1362842	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18892115	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18892115	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17329615	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17329615	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	1889	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1733	usd
CY2024Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	12470136	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	10849031	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1242	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	202	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-9833631	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7023890	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	2639636	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	3827076	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5080221	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5189918	usd
CY2024Q2	us-gaap	Revenues Revenues	605529	usd
CY2023Q2	us-gaap	Revenues Revenues	316530	usd
	us-gaap	Revenues Revenues	1220092	usd
	us-gaap	Revenues Revenues	459350	usd
CY2024Q2	us-gaap	Cost Of Revenue CostOfRevenue	166275	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	108180	usd
	us-gaap	Cost Of Revenue CostOfRevenue	335186	usd
	us-gaap	Cost Of Revenue CostOfRevenue	152613	usd
CY2024Q2	us-gaap	Gross Profit GrossProfit	439254	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	208350	usd
	us-gaap	Gross Profit GrossProfit	884906	usd
	us-gaap	Gross Profit GrossProfit	306737	usd
CY2024Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2709	usd
CY2023Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2888	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	5093	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	5385	usd
CY2024Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	721489	usd
CY2023Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	114051	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1114527	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	216727	usd
CY2024Q2	us-gaap	Management Fee Expense ManagementFeeExpense	185443	usd
CY2023Q2	us-gaap	Management Fee Expense ManagementFeeExpense	149723	usd
	us-gaap	Management Fee Expense ManagementFeeExpense	581569	usd
	us-gaap	Management Fee Expense ManagementFeeExpense	233687	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	663956	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	529950	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1542564	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	964009	usd
CY2024Q2	us-gaap	Professional Fees ProfessionalFees	158143	usd
CY2023Q2	us-gaap	Professional Fees ProfessionalFees	168933	usd
	us-gaap	Professional Fees ProfessionalFees	338065	usd
	us-gaap	Professional Fees ProfessionalFees	306730	usd
CY2024Q2	elab	Investor Relations InvestorRelations	6377	usd
CY2023Q2	elab	Investor Relations InvestorRelations	37452	usd
	elab	Investor Relations InvestorRelations	104622	usd
	elab	Investor Relations InvestorRelations	75720	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	52385	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	133654	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	173526	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	217395	usd
CY2024Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-244	usd
CY2023Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2374	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-785	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2633	usd
CY2024Q2	us-gaap	Travel And Entertainment Expense TravelAndEntertainmentExpense	57121	usd
CY2023Q2	us-gaap	Travel And Entertainment Expense TravelAndEntertainmentExpense	122655	usd
	us-gaap	Travel And Entertainment Expense TravelAndEntertainmentExpense	116229	usd
	us-gaap	Travel And Entertainment Expense TravelAndEntertainmentExpense	184170	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	1847867	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	1261680	usd
	us-gaap	Operating Expenses OperatingExpenses	3976980	usd
	us-gaap	Operating Expenses OperatingExpenses	2206456	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1408613	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1053330	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3092074	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1899719	usd
CY2024Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-26864	usd
CY2023Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	222468	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-301803	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	459246	usd
CY2024Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	30806	usd
CY2023Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	4409	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	54343	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	7045	usd
CY2024Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	64	usd
CY2023Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	349	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	150	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	5456	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	34723	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1412491	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1279858	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2809741	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2360554	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-141	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	262	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1040	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	375	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1412632	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1279596	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2808701	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2360179	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.128
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.158
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18298572	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9976725	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17814093	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9838599	shares
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	913388	usd
CY2023Q2	elab	Stock Issued During Period Value Private Placement StockIssuedDuringPeriodValuePrivatePlacement	323589	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	109907	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1279858	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	262	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	67288	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	2486346	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	772403	usd
CY2024Q2	elab	Stock Issued During Period Value Obligation To Issue Stock For Acquisition Of Intangible Assets StockIssuedDuringPeriodValueObligationToIssueStockForAcquisitionOfIntangibleAssets	838374	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	-44855	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1412491	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-141	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	2639636	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1131310	usd
	elab	Stock Issued During Period Value Private Placement StockIssuedDuringPeriodValuePrivatePlacement	1073589	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	37500	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	185068	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2360554	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	375	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	67288	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	3827076	usd
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	772403	usd
	elab	Stock Issued During Period Value Obligation To Issue Stock For Acquisition Of Intangible Assets StockIssuedDuringPeriodValueObligationToIssueStockForAcquisitionOfIntangibleAssets	838374	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	10484	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2809741	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	1040	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	2639636	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2809741	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2360554	usd
	us-gaap	Depreciation Depreciation	45960	usd
	us-gaap	Depreciation Depreciation	5825	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	10484	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	185068	usd
	us-gaap	Straight Line Rent StraightLineRent	1379	usd
	us-gaap	Straight Line Rent StraightLineRent	1378	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-301803	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	459246	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	42312	usd
	elab	Research And Development Costs For Intangible Assets ResearchAndDevelopmentCostsForIntangibleAssets	39483	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-6958	usd
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	21480	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-137295	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	183518	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	482881	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	247718	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	210111	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	375053	usd
	us-gaap	Increase Decrease In Customer Deposits IncreaseDecreaseInCustomerDeposits	-12379	usd
	us-gaap	Increase Decrease In Customer Deposits IncreaseDecreaseInCustomerDeposits	75194	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	50306	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	60000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3104757	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1654262	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9160	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11191	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	112320	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-121480	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11191	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	37500	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1073589	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1111089	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-580	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	728	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3226817	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-553636	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3326851	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1154901	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	100034	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	601265	usd
	us-gaap	Interest Paid Net InterestPaidNet	11104	usd
	us-gaap	Interest Paid Net InterestPaidNet	4898	usd
	elab	Common Stock Issued And Issuable On Acquisition Of Intangible Asset CommonStockIssuedAndIssuableOnAcquisitionOfIntangibleAsset	772247	usd
	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	838374	usd
	us-gaap	Nature Of Operations NatureOfOperations	<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0"></td><td style="width: 0.5in; text-align: left"><b>1.</b></td><td style="text-align: justify"><b>Organization and nature of operations</b></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Elevai Labs Inc. (“Elevai”) was incorporated under the laws of the State of Delaware on June 9, 2020. Elevai and its 100% owned subsidiaries, Elevai Research Inc, Elevai Skincare Inc., and Elevai BioSciences Inc., are collectively referred to in these unaudited condensed consolidated financial statements as “the Company”.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company is a skincare development company engaged in the design, manufacture, and marketing of skincare products in the skincare industry. The Company’s principal activities are developing and manufacturing skincare products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On April 29, 2024, Elevai Skincare Inc. (“Skincare”) and Elevai BioSciences Inc. (“BioSciences”) were incorporated under the laws of the state of Delaware. Elevai is the sole shareholder of Skincare and BioSciences. The purpose of Skincare is to operate the Company’s existing business. While the purpose of BioSciences is to hold and develop the Company’s intellectual property. Effective May 1, 2024, Elevai transferred its operating assets and liabilities relating to its skincare business to Skincare in exchange for common shares of Skincare.</p>
CY2024Q2	elab	Net Working Capital NetWorkingCapital	95872	usd
CY2023Q4	elab	Net Working Capital NetWorkingCapital	3622091	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-9833631	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7023890	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2809741	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2360554	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3104757	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1654262	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="text-decoration:underline">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to revenue recognition, the collectability of receivables, valuation of inventory, fair value of derivative liabilities and stock options, useful lives and recoverability of long-lived assets, and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgements about the carrying value of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from those estimates. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the unaudited condensed consolidated financial statements in the period they are determined.</p>
CY2024Q2	elab	Trade Receivable TradeReceivable	20709	usd
CY2023Q4	elab	Trade Receivable TradeReceivable	33089	usd
CY2024Q2	elab	Sales Taxes Receivable SalesTaxesReceivable	8361	usd
CY2023Q4	elab	Sales Taxes Receivable SalesTaxesReceivable	3072	usd
CY2024Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	29070	usd
CY2023Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	36161	usd
CY2024Q2	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	888129	usd
CY2023Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	957645	usd
CY2024Q2	us-gaap	Deposit Assets DepositAssets	46088	usd
CY2023Q4	us-gaap	Deposit Assets DepositAssets	113893	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	934217	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	1071538	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	923444	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1060765	usd
CY2024Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	10773	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	10773	usd
CY2024Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	10773	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	10773	usd
CY2024Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	474124	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	279514	usd
CY2024Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	290080	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	147906	usd
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	214344	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	68247	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	978548	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	495667	usd
	us-gaap	Cost Of Goods Sold Sales Type Lease CostOfGoodsSoldSalesTypeLease	152559	usd
	us-gaap	Cost Of Goods Sold Sales Type Lease CostOfGoodsSoldSalesTypeLease	73896	usd
	us-gaap	Marketing Expense MarketingExpense	92907	usd
	us-gaap	Marketing Expense MarketingExpense	64718	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	61640	usd
CY2023	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions	11191	usd
CY2023	elab	Property Plant And Equipment Foreign Currency Translation PropertyPlantAndEquipmentForeignCurrencyTranslation	61	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	72892	usd
	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions	9160	usd
	elab	Property Plant And Equipment Foreign Currency Translation PropertyPlantAndEquipmentForeignCurrencyTranslation	-87	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	81965	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8105	usd
CY2023	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Period Increase Decrease AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease	11649	usd
CY2023	elab	Equipment Foreign Currency Translation Accumulated Depreciation EquipmentForeignCurrencyTranslationAccumulatedDepreciation	19	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	19773	usd
	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Period Increase Decrease AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease	6478	usd
	elab	Equipment Foreign Currency Translation Accumulated Depreciation EquipmentForeignCurrencyTranslationAccumulatedDepreciation	-36	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	26214	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	53119	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	55751	usd
CY2024Q2	us-gaap	Capitalized Costs Accumulated Depreciation Depletion Amortization And Valuation Allowance For Relating To Oil And Gas Producing Activities CapitalizedCostsAccumulatedDepreciationDepletionAmortizationAndValuationAllowanceForRelatingToOilAndGasProducingActivities	1384	usd
CY2023Q2	us-gaap	Capitalized Costs Accumulated Depreciation Depletion Amortization And Valuation Allowance For Relating To Oil And Gas Producing Activities CapitalizedCostsAccumulatedDepreciationDepletionAmortizationAndValuationAllowanceForRelatingToOilAndGasProducingActivities	440	usd
CY2024Q1	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P10Y
CY2024Q1	elab	Purchase Price PurchasePrice	1000000	usd
CY2024Q1	us-gaap	Accounts Payable Other Current And Noncurrent AccountsPayableOtherCurrentAndNoncurrent	600000	usd
CY2024Q2	us-gaap	Construction Payable Current And Noncurrent ConstructionPayableCurrentAndNoncurrent	400000	usd
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	950000	shares
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	492850	usd
	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	173100	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	2450000	shares
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	612500	shares
	elab	Finite Lived Intangible Assets Additions FiniteLivedIntangibleAssetsAdditions	2884549	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2884549	usd
	elab	Finite Lived Intangible Assets Accumulated Amortization Additions FiniteLivedIntangibleAssetsAccumulatedAmortizationAdditions	39483	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	39483	usd
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2845066	usd
CY2023Q3	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	47986	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	79481	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	63259	usd
	us-gaap	Defined Benefit Plan Administration Expenses DefinedBenefitPlanAdministrationExpenses	60575	usd
	us-gaap	Defined Benefit Plan Administration Expenses DefinedBenefitPlanAdministrationExpenses	44353	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	11928	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	16613	usd
	elab	Lab Space Capitalized To Production Of Inventory LabSpaceCapitalizedToProductionOfInventory	6978	usd
	elab	Lab Space Capitalized To Production Of Inventory LabSpaceCapitalizedToProductionOfInventory	2293	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	79481	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	63259	usd
CY2024Q2	us-gaap	Security Deposit SecurityDeposit	10773	usd
CY2023Q4	us-gaap	Security Deposit SecurityDeposit	10773	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	80861	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	67384	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	148245	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	8182	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	140063	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	140063	usd
CY2023Q3	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	13476.75	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.115	pure
CY2023Q3	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.08	pure
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y11M1D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y5M1D
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1140634	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	596147	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	40807	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	73228	usd
CY2024Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1181441	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	669375	usd
CY2024Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	950000	usd
	elab	Consideration Payable Discount ConsiderationPayableDiscount	138548	usd
	elab	Consideration Payable Additions ConsiderationPayableAdditions	861452	usd
	elab	Consideration Payable Payment ConsiderationPayablePayment	-50000	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	42312	usd
CY2024Q2	us-gaap	Loans Payable LoansPayable	853764	usd
CY2024Q2	us-gaap	Loans Payable Current LoansPayableCurrent	348403	usd
CY2024Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	505361	usd
CY2022Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	231828	shares
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.01
CY2023Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	4
CY2023Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	231828	shares
CY2023Q2	us-gaap	Warrants And Rights Outstanding Maturity Date WarrantsAndRightsOutstandingMaturityDate	2027-04-27
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18892115	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17329615	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17329615	shares
CY2024Q2	us-gaap	Common Stocks Including Additional Paid In Capital CommonStocksIncludingAdditionalPaidInCapital	492850	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1117832	usd
CY2024Q2	us-gaap	Common Stocks Including Additional Paid In Capital CommonStocksIncludingAdditionalPaidInCapital	1117771	usd
CY2023Q1	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	62500	shares
CY2023Q1	us-gaap	Stock Option Exercise Price Decrease StockOptionExercisePriceDecrease	0.6
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	37500	usd
CY2023Q1	elab	Purchase Of Common Stock Warrants PurchaseOfCommonStockWarrants	250000	shares
CY2023Q2	us-gaap	Common Stocks Including Additional Paid In Capital CommonStocksIncludingAdditionalPaidInCapital	293579	usd
CY2024Q2	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P2Y3M25D
CY2023Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P2Y9M21D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	12500	shares
CY2024Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P10Y
CY2024Q1	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	5
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised Net Of Tax Benefit Expense StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense	16178	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	80000	shares
CY2024Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P10Y
CY2024Q1	us-gaap	Stock Option Exercise Price Decrease StockOptionExercisePriceDecrease	1
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised Net Of Tax Benefit Expense StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense	52845	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	10000	shares
CY2023Q1	us-gaap	Equity Security Fv Ni Contractual Sale Restriction Remaining Period EquitySecurityFvNiContractualSaleRestrictionRemainingPeriod	P10Y
CY2023Q1	us-gaap	Stock Option Exercise Price Decrease StockOptionExercisePriceDecrease	5
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised Net Of Tax Benefit Expense StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense	10767	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	80000	shares
CY2023Q2	us-gaap	Equity Security Fv Ni Contractual Sale Restriction Remaining Period EquitySecurityFvNiContractualSaleRestrictionRemainingPeriod	P10Y
CY2023Q2	us-gaap	Stock Option Exercise Price Decrease StockOptionExercisePriceDecrease	5
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised Net Of Tax Benefit Expense StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense	584787	usd
CY2023Q2	elab	Percentage Of Option Vesting For Remaining Period PercentageOfOptionVestingForRemainingPeriod	0.75	pure
CY2023Q2	us-gaap	Stock Issued During Period Shares Treasury Stock Reissued StockIssuedDuringPeriodSharesTreasuryStockReissued	80000	shares
CY2023Q2	us-gaap	Stock Option Exercise Price Decrease StockOptionExercisePriceDecrease	5
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0	pure
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1366167	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.08
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	234000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	14583	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.6
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	62500	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.6
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1523084	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.71
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	92500	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.54
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	266605	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.54
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1348979	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.53
	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	73548	usd
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P7Y4M9D
CY2023	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P7Y10M2D
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10484	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	185068	usd
CY2024Q2	elab	Percentage Of Authority Control PercentageOfAuthorityControl	0.10	pure
CY2024Q1	elab	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Right Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightPercentage	0.25	pure
	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	-32583	usd
	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	122355	usd
	elab	Fair Value Of Stock Options Granted FairValueOfStockOptionsGranted	1049898	usd
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Forfeited StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited	239782	shares
CY2024Q2	us-gaap	Interest Bearing Deposit Liabilities InterestBearingDepositLiabilities	22072	usd
CY2023Q4	us-gaap	Interest Bearing Deposit Liabilities InterestBearingDepositLiabilities	22455	usd
CY2024Q2	us-gaap	Line Of Credit LineOfCredit	50000	usd
	us-gaap	Line Of Credit Facility Interest Rate During Period LineOfCreditFacilityInterestRateDuringPeriod	0.20	pure
	elab	Percentage Of Subsequent Financing On Terms PercentageOfSubsequentFinancingOnTerms	0.20	pure
	elab	Percentage Of Note Amount Repaid PercentageOfNoteAmountRepaid	0.14	pure
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	elab	Non Rule10b51 Arrangement Modified NonRule10b51ArrangementModified	false
CY2024Q2	elab	Rule10b51 Arrangement Modified Rule10b51ArrangementModified	false
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill		usd
CY2023Q4	us-gaap	Loans Payable Current LoansPayableCurrent		usd
CY2023Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable		usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.128
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.158
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.240
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
	us-gaap	Other Noncash Expense OtherNoncashExpense		usd
	elab	Research And Development Costs For Intangible Assets ResearchAndDevelopmentCostsForIntangibleAssets		usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	elab	Common Stock Issued And Issuable On Acquisition Of Intangible Asset CommonStockIssuedAndIssuableOnAcquisitionOfIntangibleAsset		usd
	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1		usd
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables		usd
CY2024Q2	us-gaap	Inventory Net Of Allowances Customer Advances And Progress Billings InventoryNetOfAllowancesCustomerAdvancesAndProgressBillings		usd
CY2023Q4	us-gaap	Inventory Net Of Allowances Customer Advances And Progress Billings InventoryNetOfAllowancesCustomerAdvancesAndProgressBillings		usd
CY2023	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals		usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross		usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization		usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive		usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2023Q4	us-gaap	Loans Payable LoansPayable		usd
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001840563

Files In Submission

Name	View Source	Status
0001213900-24-068592-index-headers.html	Edgar Link	pending
0001213900-24-068592-index.html	Edgar Link	pending
0001213900-24-068592.txt	Edgar Link	pending
0001213900-24-068592-xbrl.zip	Edgar Link	pending
ea0210968-10q_elevai.htm	Edgar Link	pending
ea021096801ex31-1_elevai.htm	Edgar Link	pending
ea021096801ex31-2_elevai.htm	Edgar Link	pending
ea021096801ex32-1_elevai.htm	Edgar Link	pending
ea021096801ex32-2_elevai.htm	Edgar Link	pending
elab-20240630.xsd	Edgar Link	pending
ea0210968-10q_elevai_htm.xml	Edgar Link	completed
Financial_Report.xlsx	Edgar Link	pending
elab-20240630_cal.xml	Edgar Link	unprocessable
elab-20240630_def.xml	Edgar Link	unprocessable
elab-20240630_lab.xml	Edgar Link	unprocessable
elab-20240630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
image_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELAB
PMGC Holdings Inc. Stock $elab

2024 Q3 Form 10-Q Financial Statement

#000121390024068592 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELAB PMGC Holdings Inc. Stock $elab

2024 Q3 Form 10-Q Financial Statement

#000121390024068592 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELAB
PMGC Holdings Inc. Stock $elab